- Home
- AWRE vs BCAB Comparison
AWRE vs BCAB Comparison
Compare AWRE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWRE
- BCAB
- Stock Information
- Founded
- AWRE 1986
- BCAB 2007
- Country
- AWRE United States
- BCAB United States
- Employees
- AWRE N/A
- BCAB N/A
- Industry
- AWRE Computer Software: Prepackaged Software
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- AWRE Technology
- BCAB Health Care
- Exchange
- AWRE Nasdaq
- BCAB Nasdaq
- Market Cap
- AWRE 32.9M
- BCAB 33.5M
- IPO Year
- AWRE 1996
- BCAB 2020
- Fundamental
- Price
- AWRE $1.53
- BCAB $0.69
- Analyst Decision
- AWRE
- BCAB Buy
- Analyst Count
- AWRE 0
- BCAB 2
- Target Price
- AWRE N/A
- BCAB $5.00
- AVG Volume (30 Days)
- AWRE 55.5K
- BCAB 895.9K
- Earning Date
- AWRE 10-30-2024
- BCAB 11-07-2024
- Dividend Yield
- AWRE N/A
- BCAB N/A
- EPS Growth
- AWRE N/A
- BCAB N/A
- EPS
- AWRE N/A
- BCAB N/A
- Revenue
- AWRE $16,966,000.00
- BCAB $11,000,000.00
- Revenue This Year
- AWRE $10.98
- BCAB N/A
- Revenue Next Year
- AWRE N/A
- BCAB N/A
- P/E Ratio
- AWRE N/A
- BCAB N/A
- Revenue Growth
- AWRE N/A
- BCAB N/A
- 52 Week Low
- AWRE $1.35
- BCAB $0.67
- 52 Week High
- AWRE $2.97
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- AWRE 46.35
- BCAB 19.59
- Support Level
- AWRE $1.41
- BCAB $1.17
- Resistance Level
- AWRE $1.56
- BCAB $1.72
- Average True Range (ATR)
- AWRE 0.09
- BCAB 0.13
- MACD
- AWRE 0.01
- BCAB -0.06
- Stochastic Oscillator
- AWRE 41.07
- BCAB 2.12
About AWRE Aware Inc.
Aware Inc is a provider of software and services to the biometrics industry. The company's software products are used in government and commercial biometrics systems to identify or authenticate people. The government applications of biometrics systems include border control, visa applicant screening, law enforcement, national defense, intelligence, secure credentialing, access control, and background checks. Its commercial applications include user authentication for login to mobile devices, computers, networks, and software programs, user authentication for financial transactions and purchases. Its geographical segments include the United States, the United Kingdom, and the Rest of the world, out of which it derives maximum revenue from United States.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.